Pharmaceutical

Immune-Onc’s antibody therapy collects second FDA orphan designation

The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.

Feb 22, 2024 - 18:00
Immune-Onc’s antibody therapy collects second FDA orphan designation
The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.
Read the original article

Tags:

Previous Article

Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 

Next Article

United Therapeutics sues FDA over handling of Liquidia’s NDA

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves BMS’ Opdivo for urothelial carcinoma

FDA approves BMS’ Opdivo for urothelial carcinoma

Mar 9, 2024

Is it time to worry about Moderna?

Is it time to worry about Moderna?

Dec 15, 2023

STAT+: Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing

STAT+: Novartis is scolded by U.K. trade group for the ...

Jul 18, 2023